TY - JOUR T1 - Highlights from this issue JF - Frontline Gastroenterology JO - Frontline Gastroenterol SP - 167 LP - 168 DO - 10.1136/flgastro-2021-101849 VL - 12 IS - 3 AU - R Mark Beattie Y1 - 2021/05/01 UR - http://fg.bmj.com/content/12/3/167.abstract N2 - Steroids are an important treatment for Inflammatory Bowel Disease although have no role in maintaining remission and there are significant side effects particularly when used long term. In this issue Blackwell and colleagues discuss use and misuse. This is in the context of appropriate steroid use being regarded as a key performance indicator in the management of IBD. The paper discusses the indications for corticosteroid use, risks and strategies to reduce the use and misuse. This includes preparations and dosing regimens, an up to date discussion of toxicity and the management of side effects including how best to prevent. The authors challenge us to audit our practice which we should do and to ensure we have in place a robust team approach to the management of IBD with the early use of steroid sparing treatments where possible (see page 207) .It is well known that obesity is a risk factor for adverse health outcomes short, medium and long term. In the UK approximately one in four adults are obese and one in three is overweight as defined by body mass index. Gastrointestinal and hepatic manifestations are common and can present earlier than cardiometabolic disease. This has important implications for Gastroenterologists and Hepatologists. In this issue Ansari et al provide an excellent overview in the form of a curriculum based … ER -